Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Child & Adolescent Psychiatry
Published in: European Child & Adolescent Psychiatry 10/2015

01-10-2015 | Original Contribution

Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013

Authors: Hélène Verdoux, Elodie Pambrun, Sébastien Cortaredona, Marie Tournier, Pierre Verger

Published in: European Child & Adolescent Psychiatry | Issue 10/2015

Login to get access

Abstract

The objectives were to explore in a community-based sample of persons aged 0–25 years: (1) trends in antipsychotic prescribing, (2) characteristics of the zone of residence associated with antipsychotic prescribing rates, and (3) the pattern of antipsychotic prescribing. The study was performed using reimbursement data from the French Insurance Healthcare system. Prescribing trends were investigated over the period 2006–2013. An ecological design was used to assess the impact of the socio-economical and health resource characteristics of the zone of residence (n = 96 administrative subdivisions of French territory) on antipsychotic prescribing rates. The pattern of antipsychotic prescribing was explored in a cohort of youths newly treated with antipsychotics. Over the period 2006–2013, antipsychotic dispensing rates were stable in persons aged 0–25 years (4.8 per 1,000 in 2006 and 4.9 per 1,000 in 2013). First-generation antipsychotic dispensing rates decreased from 3.1 to 2.6 per 1,000 (OR = 0.96, 95 % CI 0.94–0.98), while second-generation antipsychotic dispensing rates increased from 2.7 to 3.4 per 1,000 (OR = 1.03, 95 % CI  1.01–1.05). Antipsychotic prescribing rates were impacted by health resource characteristics of the zone of residence in children aged 10 years and under and by socio-economical characteristics in those aged 16–20 years. In all the age groups, antipsychotics were principally started by hospital practitioners (47 %) and general practitioners (34 %). The rates of psychostimulants concomitantly prescribed with antipsychotics were lower than 5 %. In conclusion, rates of youths exposed to second-generation antipsychotics are still rising. The impact of environmental characteristics on antipsychotics prescribing and appropriateness of these prescriptions in youths should be further investigated.
Literature
1.
Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679–685CrossRefPubMed
2.
Verdoux H, Tournier M, Begaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121:4–10CrossRefPubMed
3.
Patten SB, Waheed W, Bresee L (2012) A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry 57:717–721PubMed
4.
Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML (2002) Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996–2000. J Child Adolesc Psychopharmacol 12:221–229CrossRefPubMed
5.
Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA (2004) New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753–759CrossRefPubMed
6.
Aparasu RR, Bhatara V (2005) Antipsychotic prescribing trends among youths, 1997–2002. Psychiatr Serv 56:904CrossRefPubMed
7.
Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA (2006) Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 6:79–83CrossRefPubMed
8.
Constantine R, Tandon R (2008) Changing trends in pediatric antipsychotic use in Florida’s Medicaid program. Psychiatr Serv 59:1162–1168CrossRefPubMed
9.
Pringsheim T, Lam D, Patten SB (2011) The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol 21:537–543CrossRefPubMed
10.
Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW (2012) Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 57:52–58PubMed
11.
Olfson M, Blanco C, Liu SM, Wang S, Correll CU (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69:1247–1256CrossRefPubMed
12.
Murphy AL, Gardner DM, Cooke C, Kisely S, Hughes J, Kutcher SP (2013) Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 13:198PubMedCentralCrossRefPubMed
13.
Ronsley R, Scott D, Warburton WP, Hamdi RD, Louie DC, Davidson J, Panagiotopoulos C (2013) A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996–2011. Can J Psychiatry 58:361–369PubMed
14.
Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002–1009CrossRefPubMed
15.
Acquaviva E, Legleye S, Auleley GR, Deligne J, Carel D, Falissard BB (2009) Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 9:72PubMedCentralCrossRefPubMed
16.
Schubert I, Lehmkuhl G (2009) Increased antipsychotic prescribing to youths in Germany. Psychiatr Serv 60:269PubMed
17.
Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M (2009) Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 19:757–764CrossRefPubMed
18.
Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014) Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005–2012. Dtsch Arztebl Int 111:25–34PubMedCentralPubMed
19.
Steinhausen HC, Bisgaard C (2014) Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 129:221–231CrossRefPubMed
20.
21.
Verdoux H, Tournier M, Bégaud B (2009) Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues. Epidemiol Psichiatr Soc 18:107–113PubMed
22.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765–1773PubMedCentralCrossRefPubMed
23.
Harrison JN, Cluxton-Keller F, Gross D (2012) Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care 26:139–145PubMedCentralCrossRefPubMed
24.
Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, Fuchs DC, Ray WA (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 70:1067–1075CrossRefPubMed
25.
Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M (2013) Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 22:457–479CrossRefPubMed
26.
Clavenna A, Rossi E, Derosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166:339–347CrossRefPubMed
27.
Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, de Jong-van den Berg LT (2008) Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59:554–560CrossRefPubMed
28.
Constantine RJ, Boaz T, Tandon R (2010) Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 32:949–959CrossRefPubMed
29.
Brown AF, Ettner SL, Piette J, Weinberger M, Gregg E, Shapiro MF, Karter AJ, Safford M, Waitzfelder B, Prata PA, Beckles GL (2004) Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev 26:63–77CrossRefPubMed
30.
Crump C, Sundquist K, Sundquist J, Winkleby M (2011) Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. Ann Epidemiol 21:231–237PubMedCentralCrossRefPubMed
31.
Bocquier A, Cortaredona S, Verdoux H, Casanova L, Sciortino V, Nauleau S, Verger P (2014) Social inequalities in early antidepressant discontinuation. Psychiatr Serv 65:618–625CrossRefPubMed
32.
Hsu YC, Chien IC, Tan HK, Lin CH, Cheng SW, Chou YJ, Chou P (2013) Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Soc Psychiatry Psychiatr Epidemiol 48:1889–1896CrossRefPubMed
33.
Martin-Latry K, Begaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19:256–265CrossRefPubMed
34.
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y (2010) French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 58:286–290CrossRefPubMed
35.
World Health Organization (1993) The health of young people. A challenge and a promise. WHO, Geneva
36.
World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology (2007) About the ATC/DDD system. Norwegian Institute of Public Health, Oslo
37.
38.
39.
40.
Verdoux H, Cougnard A, Thiebaut A, Tournier M (2011) Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. Pharmacopsychiatry 44:96–101CrossRefPubMed
41.
Tournier M, Crott R, Gaudron Y, Verdoux H (2013) Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatr Scand 127:365–372CrossRefPubMed
42.
Hoffman E, Sen P, Weinberg C (2001) Within-cluster resampling. Biometrika 88:1121–1134CrossRef
43.
Follmann D, Proschan M, Leifer E (2003) Multiple outputation: inference for complex clustered data by averaging analyses from independent data. Biometrics 59:420–429CrossRefPubMed
44.
45.
SAS software version 9.3. SAS Institute Inc., Cary
46.
Olfson M, Crystal S, Huang C, Gerhard T (2010) Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49:13–23PubMed
47.
Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM (2012) Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull 38:1118–1123PubMedCentralCrossRefPubMed
48.
Verdoux H (2007) The current state of adult mental health care in France. Eur Arch Psychiatry Clin Neurosci 257:64–70CrossRefPubMed
49.
50.
Bocquier A, Cortaredona S, Verdoux H, Sciortino V, Nauleau S, Verger P (2013) Social inequalities in new antidepressant treatment: a study at the individual and neighborhood levels. Ann Epidemiol 23:99–105CrossRefPubMed
51.
Verdoux H, Gaudron Y, Tournier M (2011) Transition in care in persons with antidepressant prescription in naturalistic conditions. Fam Pract 28:400–405CrossRefPubMed
52.
Patel NC, Crismon ML, Hoagwood K, Johnsrud MT, Rascati KL, Wilson JP (2006) Physician specialty associated with antipsychotic prescribing for youths in the Texas Medicaid program. Med Care 44:87–90CrossRefPubMed
53.
Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, Panei P, Autret-Leca E (2008) Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 64:311–317CrossRefPubMed
54.
Faber A, de Jong-van den Berg LT, van den Berg PB, Tobi H (2005) Psychotropic co-medication among stimulant-treated children in The Netherlands. J Child Adolesc Psychopharmacol 15:38–43CrossRefPubMed
55.
Schmidt-Troschke S, Ostermann T, Melcher D, Schuster R, Erben C, Matthiessen P (2004) The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions. Gesundheitswesen 66:387–392CrossRefPubMed
Metadata
Title
Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013
Authors
Hélène Verdoux
Elodie Pambrun
Sébastien Cortaredona
Marie Tournier
Pierre Verger
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
European Child & Adolescent Psychiatry / Issue 10/2015
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-014-0668-y

Other articles of this Issue 10/2015

European Child & Adolescent Psychiatry 10/2015 Go to the issue

Review

ESCAP Expert Paper: New developments in the diagnosis and treatment of adolescent anorexia nervosa—a European perspective

Original Contribution

Classifying adolescent attention-deficit/hyperactivity disorder (ADHD) based on functional and structural imaging

Editorial

Anorexia nervosa through the looking glass of the draft ICD-11 diagnostic criteria: a disorder in transition

Original Contribution

Evaluating change in symptomatic and functional level of children and youth with emotional disorders: a naturalistic observation study

Original Contribution

Investigation of a bifactor model of the Strengths and Difficulties Questionnaire

Original Contribution

Maternal heavy alcohol use and toddler behavior problems: a fixed effects regression analysis